key: cord-0992211-7inwk5d7
authors: Lladó, Iñigo; Fernández-Bernáldez, Alberto; Rodríguez-Jiménez, Pedro
title: “Varicella zoster virus reactivation and mRNA vaccines as a trigger”. Reply to: Herpes-Zoster reactivation after mRNA-1273 (Moderna) SARS-CoV-2 Vaccination
date: 2021-07-22
journal: JAAD Case Rep
DOI: 10.1016/j.jdcr.2021.07.011
sha: 0a49592d32ccbbbe1e68d8002e016e5ed02fa038
doc_id: 992211
cord_uid: 7inwk5d7

nan

53 Surprisingly, most of the patients were middle-aged (i.e., fifth to sixth decades of life), 54 as someone would expect to observe the highest incidence rates among the oldest 55 patients. Time to onset of symptoms was highly variable, ranging from 1 to 26 days and 56

showing a median of 6 days. The difference in the time of onset having received the 57 first or the second vaccine dose was not consistent between the series. Lastly, the 58 sample distribution was, overall, highly heterogeneous in terms of comorbidities, past 59 history of herpes zoster or previous VZV vaccination. 

Herpes-Zoster reactivation after mRNA-1273

Moderna) SARS-CoV-2 Vaccination

20 Post-COVID-19 vaccine-related 99 shingles cases seen at the Las Vegas Dermatology clinic and sent to us via social 100 media

Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: 103 A registry-based study of 414 cases

Reactivation of varicella 106 zoster virus after vaccination for sars-cov-2. Vaccines

Herpes zoster 108 following BNT162b2 mRNA COVID-19 vaccination in patients with 109 autoimmune inflammatory rheumatic diseases: a case series

Varicella-zoster virus reactivation after SARS-CoV-2 114

BNT162b2 mRNA vaccination: Report of 5 cases

BNT162b2 mRNA COVID-19 vaccine. J Eur Acad Dermatology Venereol

J o u r n a l P r e -p r o o f